Mechlorethamine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Most sources consider that mothers receiving antineoplastic therapy should not breastfeed, especially with alkylating agents such as mechlorethamine.[1] Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding from mechlorethamine mothers should not breastfed during therapy with mechlorethamine therapy, including topical application.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
1.
Pistilli B, Bellettini G, Giovannetti E, et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding? Cancer Treat Rev. 2013;39:207–11. [PubMed: 23199900]
Substance Identification
Substance Name
Mechlorethamine
CAS Registry Number
51-75-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Alkylating Agents
Irritants
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
